

# Report to the Meeting of the

# Oxford Health NHS Foundation Trust

**BOD 42/2021**

(Agenda item: 16)

# Board of Directors

**09 June 2021**

**Chief Medical Officer’s Summary Report**

**Including (for approval) an update on Medical Appraisal and Revalidation**

**For: Assurance and Approval**

**Executive Summary**

These are key developments within 1) Research and Development, 2)Pharmacy and Medicines Management and 3) Medical Professionalism, a summary from each area is provided below and appended is a Medical Appraisal and Revalidation report for NHSE, requiring Board signature.

**1.0 Research and Development Dept update (June 2020)**

1.1 Oxford Health NIHR Biomedical Research Centre (BRC) stage one application submitted in May for 11 potential themes (£45m). Outcome and invitations to stage two due 4th August 2020.

1.2 The R&D annual returns complete and submitted for:

* Oxford Health NIHR Biomedical Research Centre (BRC)
* Oxford cognitive health Clinical Research Facility (CRF)
* Applied Research Collaboration Oxford and Thames Valley (OxTV)
* MedTech and In Vitro Diagnostic Co-operatives (MIC)

1.3 OHFT’s Director of R&D, Prof John Geddes is stepping down after 10 years, at the end of June. Amongst many achievements he had led the development of the CRF, secured only the second national Mental Health BRC, brought national and international research experts to Oxford, and grown the Department’s research income from around £1m to over £12m. John will stay connected as BRC Director and with his appointment as WA Handley Professor of Psychiatry & Fellow of Merton College. Until the future appointment of a successor, I will take on the Role of Director of R&D.

**2.0 Pharmacy Dept Update – June 2021**

2.1 The medicines optimization strategy & governance process is being reviewed as part of pandemic recovery, to ensure that there is a robust medicine governance, but which is not overly onerous. The current work is framed by the *WHO Global Patient Safety Challenge: Medication without Harm*, with key areas of Polypharmacy, High-risk situations, and transitions of care. All projects will link with the trust’s new e-prescribing system. The trust has CQC engagement session for compliance with medicines safety plans and assurances.

2.2 OHFT collaboration with the ICS plan is structured around:

*1) Strategy, Leadership and Governance*

*2) Medicines Optimisation - Safety and Value*

*3) Digital*

*4) Pharmacy workforce*.

There is a requirement to submit a plan to NHSE/I to support the Integrating Pharmacy & Medicines Optimisation (IPMO) programme across BOB ICS.

2.3 A new element of the medicine’s strategy will specifically cover sustainability. This will support the trust’s Green Alert initiative to cover increasing recycling of medicines packaging and consumables, reducing waste and pollution, reducing the carbon footprint of medicines logistics and supply chain, and incorporating an environmental impact to formulary decision making. A plan to socialise the concept of “pharmacology” is underway.

**3.0 Medical Professionalism**

3.1 A NHSE submission for doctors’ revalidation and appraisal (appended to this report) has been written to be signed by the Chairman/CEO on the Boards behalf. Approval is requested today. The summary is that during the pandemic there was an exemption for doctors annual appraisal, nevertheless for the 188 doctors connected to OHFT as their GMC’s Designated Body, the 2020/21 NHSE submission is that 99% of doctors are up to date in completing their annual appraisal. These are approved reasons for exemption and no letters of non-engagement sent 2020/2021.

3.2 There are currently insufficient trained Trust Appraisers and administration for the OHFT’s Responsible Officer to discharge a timely and high-quality process. This will be part of the 2021/22 medical professional and HR development/review, linked with the appointment of a new Chief People Officer.

**Recommendation**

The Board is asked to take assurance from the developments in this report and for required NHE/CQC compliance.

**Author and Title: Dr Karl Marlowe, Chief Medical Officer**

**Lead Executive Director: Chief Medical Officer**

***Strategic Objectives/Priorities*** *– this report relates to or provides assurance and evidence against the following Strategic Objective(s)/Priority(ies) of the Trust*

*1) Quality - Deliver the best possible care and health outcomes*

*2) People - Be a great place to work*

*3) Sustainability – Make best use of our resources and protect the environment*

*4) Research and Education – Become a leader in healthcare research and education*